ИСТИНА

Discrepancy between objective data and subjective experience is rather often in patients with schizophrenia. Especially it concerns the situation when the treatment target is the negative domain of symptoms. In the previous study of ipidacrine – nonselective anticholinergic agent, in patients with schizophrenia and prominent cognitive deterioration, we’ve seen significant positive changes in PANSS (positive and negative symptoms scale) scores, assessing emotions (Morozova et al, 2008). This study targeted the negative symptoms. Materials and methods: 26 patients (ICD10-F 20.0) were included into the 8 weeks open-labeled study of 20 mg of ipidacrine daily, added to base treatment (males – 13 (50%) female-13 (50%), PANSS at the beginning 75,8 (SD -12,4). The instruments of assessments were PANSS, Brief Assessment of cognition in Schizophrenia-BACS, narrative of patient’s impression on their emotions and motivation. Results: 21 completed the protocol. There were significant changes in PANSS negative score and BACS T-score and no changes in positive score. There was no correlation between improvement in negative and BACS score. Patients reported the following: “better understand humor”, ”could start to visit dentist”, “ easier to communicate, not so constrained” , “more alert”, “feel more comfort inside”, “better time-planning, less mess in my life”, “my mind is not foggy anymore”, “my thinking goes smoothly”, “ can plan and fulfill plans”, “can remember, what I ate on breakfast”, “ don’t forget to take my medication anymore”. Conclusion: the patients feel the effects of low dose of ipidacrine as integrally improvement of wellbeing, each in important for him field: emotional, motivational or cognitive. https://cslide.ctimeetingtech.com/epa20/attendee/confcal/session/calendar?q=rupchev